StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) income statement

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30206% above fair value
$127.16+2.49 (+2.00%)

Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –

Protagonist Therapeutics, Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
20.7%
Net margin
29.4%
Return on equity, FY2025
-20.2%

Financial strength

Current ratio
21.71
Debt to equity
–
Debt to assets
–
Cash to current liabilities
1129.8%

Valuation

P/E ratio
123.5
Price to sales
29.18
Price to book
9.78
Dividend yield
–

See a number that looks wrong?